Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): Increased invasiveness may contribute to poor prognosis

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1629-1634

  Xu, Feng Ji ^a   Stack, Sharon ^b   Boyer, Cinda ^c   O'Briant, Kathy ^c   Whitaker, Regina ^c   Mills, Gordon B ^a   Yu, Yin Hua ^a   Bast Jr , Robert C ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MATRIX METALLOPROTEINASE; NEU DIFFERENTIATION FACTOR;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, CD44; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; COLLAGEN; COLLAGENASES; DRUG COMBINATIONS; FEMALE; GENES, ERBB-2; GLYCOPROTEINS; GROWTH INHIBITORS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LAMININ; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEUREGULINS; PHOSPHORYLATION; PLASTICS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOGLYCANS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0030879101     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45: 649-657, 1986.
2. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tryosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington, DC), 230: 1132-1139, 1985.
3. Gasparini, G., Gullick, W. J., Maluta, S., Palma, P. D., Caffo, O., Leonardi, E., Boracchi, P., Pozza, F., Lemoine, N. R., and Bevilacqua, P. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma: an immunochemical study. Eur. J. Cancer, 30: 16-22, 1994.
4. Rubin, S. C., Finstad, C. I., Wong, G. Y., Almadrones, L., Plante, M., and Lloyd, K. O. Prognostic significance of HER-2/neu expression in advanced ovarian cancer. Am. J. Obstet. Gynecol., 168: 162-169, 1993.
5. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu pro-oncogene in human breast and ovarian cancer. Science (Washington, DC), 244: 707-712, 1989.
6. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinny, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
7. Xu, F. J., Lupu, R., Rodriguez, G. C., Whitaker, R. S., Boente, M. P., Berchuck, A., Yu, Y., DeSombre, K. A., Boyer, C. M., and Bast, R. C., Jr. Antibody induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB2 (HER-2/neu) gene product p185. Int. J. Cancer, 53: 401-408, 1993.
8. Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., and Yarden, Y. Isolation of the Neu/HER-2 stimulatory ligand: a 44-kd glycoprotein that induces differentiation of mammary tumor cells. Cell, 69: 205-216, 1992.
9. erbB2. Science, (Washington, DC), 256: 1205-1210, 1992.
10. Bacus, S. S., Huberman, E., Chin, D., Kiguchi, K., Simpson, S., Lippman, M., and Lupu, R. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ., 3: 401-411, 1992.
11. Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J., 12: 961-971, 1993.
12. Carraway, K. L., III, Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Camley, L. C., and Cerione, R. A. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem., 269: 14303-14306, 1994.
13. Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 269: 14661-14665, 1994.
14. Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., Fendly, B. M., Bauer, K. D., and Sliwkowski, M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56: 1457-1465, 1996.
15. Drebin, J. A., Link, V. C., and Greene, M. I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene, 2: 387-394, 1988.
16. Bacus, S., Stancovski, I., Huberman, E., Chin, D., Hurwitz, E., Mills, G. B., Ullrich, A., Sela, M., and Yarden, Y. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res., 52: 2580-2589, 1992.
17. Hudziak, R. M., Lewis, G. D., Winget, E., Fendly, B. M., Shepard, H. M., and Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast-tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
18. Aaronson, S. A. Growth factors and cancer. Science (Washington, DC), 254: 1146-1152, 1991.
19. Harris, J. R., Lippman, M. E., Veronesi, U., and Willet, W. Breast Cancer (3). N. Engl. J. Med., 327: 473-480, 1992.
20. Bacus, S. S., Gudkov, A. V., Zelnick, C. R., Chin, D., Stern, R., Stancovski, I., Peles, E., Ben-Baruch, N., Farbstein, H., Lupu, R., Wen, D., Sela, M., and Yarden, Y. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res., 53: 5251-5261, 1993.
21. Dano, K., Andreasen, P. A., Grondahl-Hansen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
22. Tryggvason, K., Hoyhtya, M., and Salo, T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217, 1987.
23. Liotta, L. A., Rao, C. N., and Wewer, U. M. Biochemical interactions of tumor cells with the basement membrane. Annu. Rev. Biochem., 55: 1037-1057, 1986.
24. Fogh, J., and Trempe, G. New human tumor cell lines. In: J. Fogh (ed.), Human Tumor Cells in Vitro, pp. 115-159. New York: Plenum Press, 1975.
25. McKenzie, S. T., Marks, P. J., Lam, T., Morgan, J., Panicali, D. L., Trimpe, K. L., and Camey, W. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product p185. Oncogene, 4: 543-548, 1989.
26. Heussen, C., and Dowdle, E. B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem., 102: 196-202, 1980.
27. Xu, F. J., Boyer, C., Bae, D. S., Wu, S., Greenwald, M., O'Briant, K., Yu, Y. H., Mills, G. B., and Bast, R. C., Jr. The tyrosine kinase activity of the c-erbB2 gene product (p185) is required for growth inhibition by anti p185 antibodies but not for cytotoxicity of an anti p185 ricin A chain immunotoxins. Int. J. Cancer, 59: 242-247, 1994.
28. Tzahar, E., Levkowitz, G., Karunagaran, D., Yi, L., Peles, E., Lavi, S., Chang, D., Liu, N., Yayon, A., Wen, D., and Yarden, Y. erbB3 and erbB4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J. Biol. Chem., 269: 25226-25233, 1994.
29. Wen, D., Peles, E., Cupples, R., Suggs, S. V., Bacus, S. S., Luo, Y., Trail, G., Hu, S., Silbiger, S. M., Levy, R. B., Koski, R. A., Lu, H. S., and Yarden, Y. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell, 69: 559-572, 1992.